Advances in CAR T-Cell Therapy and Bispecifics for Relapse/Refractory Multiple Myeloma: Insights From ESMO Congress 2024

by | Sep 17, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.
Read More

Submit a Comment